| Sarah Aguirre, | |
|
11501 Dolan Ave, Downey, CA 90241-4921 | |
| (562) 923-7894 | |
| Not Available |
| Full Name | Sarah Aguirre |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 11501 Dolan Ave, Downey, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164894952 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Aguirre, 11501 Dolan Ave, Downey, CA 90241-4921 Ph: (562) 923-7894 | Sarah Aguirre, 11501 Dolan Ave, Downey, CA 90241-4921 Ph: (562) 923-7894 |
News Archive
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
FibroGen, Inc., today announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).
Researchers at the University of Georgia have discovered that dormancy of the parasite Trypanosoma cruzi prevents effective drug treatment for Chagas disease, which kills more than 50,000 people each year in Central and South America and is a growing threat in the United States and Europe.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).
Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes provide further evidence that reduced hippocampal volume is a consistent feature of schizophrenia.
› Verified 3 days ago
Paul William Luna, Counselor Medicare: Not Enrolled in Medicare Practice Location: 11501 Dolan Ave, Downey, CA 90241 Phone: 562-923-7894 Fax: 562-869-3400 | |
Thayna Villapudua, Counselor Medicare: Not Enrolled in Medicare Practice Location: 8700 Cleta St, Downey, CA 90241 Phone: 562-862-9766 Fax: 562-869-4110 | |
Mrs. Nelly Salazar, Counselor Medicare: Not Enrolled in Medicare Practice Location: 11500 Paramount Blvd, Living With Hope Dept., Downey, CA 90241 Phone: 562-923-4545 | |
Rosalba Raygoza, Counselor Medicare: Not Enrolled in Medicare Practice Location: 11500 Paramount Blvd, Downey, CA 90241 Phone: 562-923-4545 Fax: 562-862-7205 | |
Claudia Marina Ramos, Counselor Medicare: Not Enrolled in Medicare Practice Location: 11500 Paramount Blvd, Downey, CA 90241 Phone: 562-923-4545 | |
Ms. Corrine Nichelle Alanis, Counselor Medicare: Not Enrolled in Medicare Practice Location: 11500 Paramount Blvd, Downey, CA 90241 Phone: 562-923-4545 | |
Jazmin E Davalos, Counselor Medicare: Not Enrolled in Medicare Practice Location: 8700 Cleta St, Downey, CA 90241 Phone: 562-862-9766 Fax: 562-862-5137 |